lopinavir-ritonavir drug combination
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
OBJECTIVES
We evaluated a monotherapy maintenance regimen with lopinavir/ritonavir versus continuing current combined…
We assessed the suitability of 4β‐hydroxycholesterol (4βOH‐C) as an endogenous cytochrome P450 3A (CYP3A) phenotyping metric. 4…
Background Risk factors for loss of virological response in patients receiving lopinavir/ritonavir (LPV/r) monotherapy as…
Recent studies have demonstrated that human immunodeficiency virus (HIV) protease inhibitors (PIs) exert inhibitory effects on…
AbstractBackground: Lopinavir is a protease inhibitor indicated for the treatment of HIV infection. It is coformulated with low…
BACKGROUND
The extent to which drug-resistant human immunodeficiency virus type 1 (HIV-1) acquired through mother-to-child…
Objectives:To present direct manufacturing costs and price calculations of individual antiretroviral drugs, enabling those…
The incorporation of poorly soluble drugs into convenient oral dosage forms is one of the biggest challenges encountered in drug…
Objective: To assess the pharmacokinetic interaction of saquinavir and lopinavir/ritonavir. Design: Patients from the Frankfurt…
Lopinavir/ritonavir was administered to 35 HIV-infected patients after therapeutic failure with other protease inhibitors. The…